Fig. S2 from Single Agent and Synergistic Activity of the 'First-in-Class' Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

Autor:	Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich, Yuko Kono, Sadakatsu Ikeda, Jason K. Sicklick, Adam M. Burgoyne, Shweta Joshi, Alok R. Singh
Rok vydání:	2023
DOI:	10.1158/1535-7163.22507045.v1
Popis:	SF1126 and Sorafenib inhibit cell cycle progression by inducing apoptosis
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03307a9deb77b1c3ff83e6d4c494c1fe https://doi.org/10.1158/1535-7163.22507045.v1 Zobrazit plný text záznamu